PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as ...
RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...
A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". Health Canada Grants Priority Review Designation for SUBLOCADE™ SLOUGH, ...
Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered ...
Add Yahoo as a preferred source to see more of our stories on Google. Dr. Andrew Herring, who works in the addiction clinic at Highland Hospital in Oakland, Calif., says that Sublocade, an injectable ...
RICHMOND, Va., May 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the publication of a study "Monthly Buprenorphine Depot Injection (SUBLOCADE) for Opioid Use Disorder During ...
RICHMOND, Va., Oct. 7, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the Prior Approval Supplement (PAS) for SUBLOCADE® (buprenorphine extended-release) injection submitted by ...
OAKLAND, Calif. — Dr. Andrew Herring has a clear goal walking into every appointment with patients seeking medication to treat an opioid use disorder: persuade them to get an injection of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results